<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447784</url>
  </required_header>
  <id_info>
    <org_study_id>TH002</org_study_id>
    <nct_id>NCT01447784</nct_id>
  </id_info>
  <brief_title>ToleroMune House Dust Mites (HDM) Exposure Chamber Study</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune HDM in House Dust Mite Allergic Subjects Following Challenge With House Dust Mite Allergen in an Environmental Exposure Chamber.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cetero Research, San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      House Dust Mites (HDM) are arachnids that infest bedding, carpet, upholstered furniture and
      fabric. Like many other allergens, exposure to HDM allergens in sensitised patients is
      associated with poorer lung function, greater medication requirements and more asthma
      symptoms as well as chronic rhinosinusitis symptoms. In contrast to other allergens, there is
      evidence that HDMA leads to the development of asthma, in addition to exacerbating
      pre-existing asthma in HDM-sensitised patients.

      ToleroMune HDM is a novel, synthetic, allergen-derived peptide desensitising vaccine,
      currently being developed for the treatment of HDM allergy

      This study will look at the efficacy, safety and tolerability of three doses of ToleroMune
      HDM in HDM allergic subjects following challenge with HDM allergen in an Environmental
      Exposure Chamber (EEC)).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a randomised, double-blind, placebo-controlled, parallel group
      study to evaluate the safety and tolerability of ToleroMune HDM in HDM allergic subjects with
      allergic rhinoconjunctivitis. The efficacy of ToleroMune Ragweed will be explored in subjects
      using an EEC.

      The study will consist of 3 study periods. In Period 1, Screening will be performed up to a
      maximum of 16 weeks before randomisation and may consist of one or two visits to the clinic,
      at the Investigator's discretion. Baseline Challenge will consist of 3 visits to the EEC.
      Eligible subjects will complete a daily diary card at home for two weeks following the final
      visit to the EEC.

      In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be
      randomised to one of four groups and will receive treatment over 11 visits in 3 dosing
      periods for each subject. Within each dosing period visits will take place at intervals of 4
      weeks (28Â±2 days). There will also be two EEC visits during the treatment period and one post
      treatment EEC visit. Following the final visit to the EEC, subjects will complete a daily
      diary card at home for two weeks.

      In Period 3, Follow-up will be conducted 16-21 days after the final EEC visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Score</measure>
    <time_frame>Up to 47 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scores for nasal and non-nasal symptoms</measure>
    <time_frame>Up to 47 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Score</measure>
    <time_frame>Up to 19 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Score</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDM specific IgA</measure>
    <time_frame>Up to 53 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDM specific IgE</measure>
    <time_frame>Up to 53 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDM specific IgG4</measure>
    <time_frame>Up to 53 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Upto 53 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune HDM Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune HDM Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune HDM Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ToleroMune HDM</intervention_name>
    <description>Intradermal injection 1 x 11 administrations 4 weeks apart</description>
    <arm_group_label>ToleroMune HDM Dose 1</arm_group_label>
    <arm_group_label>ToleroMune HDM Dose 2</arm_group_label>
    <arm_group_label>ToleroMune HDM Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal injection 1 x 11 administrations 4 weeks apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Male or female, aged 18-65 years.

          -  Minimum 1-year documented history of rhinoconjunctivitis on exposure to HDM.

          -  Positive skin prick test to Der p allergen.

          -  Minimum qualifying rhinoconjunctivitis symptom scores

        Exclusion criteria

          -  History of asthma (asthma in childhood .

          -  A history of anaphylaxis to HDM allergen.

          -  Subjects with an FEV1 &lt;80% of predicted.

          -  Subjects who cannot tolerate baseline challenge in the EEC.

          -  Subjects for whom administration of epinephrine is contra-indicated (e.g. subjects
             with acute or chronic symptomatic coronary heart disease or severe hypertension).

          -  A history of severe drug allergy, severe angioedema or anaphylactic reaction to food.

          -  A history of any significant disease or disorder (e.g. cardiovascular, pulmonary,
             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,
             neoplastic/malignant, psychiatric, major physical impairment).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepen Patel, MD, CCFP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <last_update_submitted>July 16, 2013</last_update_submitted>
  <last_update_submitted_qc>July 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDM allergy</keyword>
  <keyword>Rhinoconunctivitis</keyword>
  <keyword>Environmental Exposure Chamber</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>ToleroMune HDM</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

